Empagliflozin monotherapy in drug-naive patients with Type 2 diabetes

被引：0
|
作者：
Roden, M. [1 ]
Weng, J. [2 ]
Merker, L. [3 ]
Christiansen, A. Vedel [4 ]
Roux, F. [5 ]
Salsali, A. [6 ]
Kim, G. [6 ]
Stella, P. [6 ]
Woerle, H. J. [6 ]
Broedl, U. C. [6 ]
机构：
[1] Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China
[3] Diabet & Nierenzentrum, Dormagen, Germany
[4] Boehringer Ingelheim Danmark AS, Copenhagen, Denmark
[5] Boehringer Ingelheim France, Reims, France
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P191
引用
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [1] Empagliflozin Monotherapy Improves Glucose Control in Drug-Naive Patients With Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Eilbracht, Jens
    Delafont, Bruno
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A280 - A280
  • [2] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A69 - A69
  • [3] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael W.
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [4] Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
    Pi-Sunyer, F. Xavier
    Schweizer, Anja
    Mills, David
    Dejager, Sylvie
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) : 132 - 138
  • [5] Combinations of empagliflozin/linagliptin for 24 weeks in drug-naive subjects with Type 2 diabetes
    Lewin, A.
    DeFronzo, R. A.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [6] Initial combination of metformin, sitagliptin, and empagliflozin in drug-naive patients with type 2 diabetes: Safety and metabolic effects
    Lim, Soo
    Sohn, Minji
    Shin, Yujin
    Ferrannini, Ele
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 757 - 762
  • [7] Efficacy of vildagliptin in drug-naive patients with type 2 diabetes
    Dejager, S.
    Baron, M. A.
    Razac, S.
    Foley, J. E.
    Dickinson, S.
    Schweizer, A.
    [J]. DIABETOLOGIA, 2006, 49 : 479 - 480
  • [8] Once-daily saxagliptin monotherapy improves glycemic control in drug-naive patients with type 2 diabetes
    Rosenstock, Julio
    Aguilar-Salinas, Carlos A.
    Klein, Eric
    List, James
    Blauwet, Mary Beth
    Chen, Roland
    [J]. DIABETES, 2008, 57 : A154 - A154
  • [9] Fixed dose combinations of empagliflozin and linagliptin for 52 weeks in drug-naive subjects with type 2 diabetes
    Lewin, A.
    DeFronzo, R.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2014, 57 : S346 - S347
  • [10] REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAIVE SUBJECTS WITH TYPE 2 DIABETES
    Kutoh, Eiji
    Wada, Asuka
    Hayashi, Jyunka
    [J]. ENDOCRINE PRACTICE, 2018, 24 (12) : 1063 - 1072
12345